1. Al-Marzouki, S, Roberts, I, Marshall, T, et al. The effect of scientific misconduct on the results of clinical trials: A Delphi survey. Contemp Clin Trials. 2005;26:331–337.
2. Albain, KS, Nag, S, Calderillo-Ruiz, G, et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. J Clin Oncol. 2004;22 (Suppl):A510.
3. Blohmer, J, Kaufman, M, Eiermann, W et al. , First analysis of the event-free survival of the GeparDuo-study: Neoadjuvant doxorubicin / cyclophosphamide followed by docetaxel (AC-Doc) versus dose-dense doxorubicin and docetaxel (ADoc) in breast cancer. Abstract from 27 Deutscher Krebskongress Berlin. 2006.
4. Burstein, HJ, Spigel, D, Kindsvogel, K, et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: A randomized phase II study. Breast Cancer Res Treat. 2005;94:S6.
5. Cameron, D, Stein, S, Zaks, T et al. , Lapatinib plus capecitabine shows superior efficacy compared to capecitabine alone in patients with ErbB2 positive advanced or metastatic breast cancer initial biomarker data. Proceedings from the 2006 annual San Antonio Breast Cancer Symposium, December 15, 2006. (Abstract 2).
6. Carmichael, J. Current issues in cancer: Cancer chemotherapy: Identifying novel anticancer drugs. BMJ. 1994;308:1288–1290.
7. Centre for Reviews and Dissemination (CRD). Undertaking systematic reviews of research on effectiveness. Report No. 4. York: CRD; 2001.
8. Chalmers, I. Underreporting research is scientific misconduct. JAMA. 1990;263:1405–1408.
9. Dickersin, K, Olson, CM, Rennie, D, et al. Association between time interval to publication and statistical significance. JAMA. 2002;287:2829–2831.
10. Geyer, CE, Forster, J, Lindquist, D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–2743.
11. Geyer, CE, Martin, A, Newstat, B, et al. Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): Genomic and updated efficacy data. J Clin Oncol. 2007;25 (Suppl):A1035.
12. Henderson, IC, Berry, D. Demetri GD. Improved disease free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer (abstract). Proc Am Soc Clin Oncol. 1998;17:A390.
13. Henderson, I, Berry, D, Demetri, G, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node positive primary breast cancer. J Clin Oncol. 2003;21:976–983.
14. Jackisch, C, von Minckwitz, G, Eidtmann, H, et al. Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: Second interim analysis. Clin Breast Cancer. 2002;3:276–280.
15. Krzyzanowska, M, Pintilie, M. Tannock I. Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA. 2003;290:495–501.
16. Lyons, JA, Silverman, P, Remick, S, et al. Toxicity results and early outcome data on a randomized phase II study of docetaxel +/− bevacizumab for locally advanced, unresectable breast cancer. J Clin Oncol. 2006;24:133S.
17. Mamounas, EP. Evaluating the use of paclitaxel following doxorubicin/ cyclophosphamide in patients with breast cancer and positive axillary node (abstract). Proceedings from the NIH Consensus Development Conference on Adjuvant Therapy for Breast Cancer; November 1–3, 2000, Bethesda, MD.
18. Mamounas, EP, Bryant, J, Lembersky, BC, et al. Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. Proc Am Soc Clin Oncol. 2003;22:A12.
19. Martin, M, Pienkowski, T, Mackey, J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302–2313.
20. McIntyre, J, Moral, M, Bozzo, J. Combination therapy with valproic acid in cancer: Initial clinical approach. Drugs Fut. 2007;32:45–50.
21. Miller, KD, Wang, M, Gralow, J, et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat. 2005;94:S6.
22. Moher, D. Reporting research results: A moral obligation for all researchers. Can J Anesth. 2007;54:331–335.
23. Moinpour, C, Wu, J, Donaldson, G, et al. Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): Quality of life (QoL) and pain palliation results from the global phase III study. J Clin Oncol. 2004;22:32S.
24. Montori, VM, Devereaux, PJ, Adhikari, NKJ, et al. Randomized trials stopped early for benefit: A systematic review. JAMA. 2005;294:2203–2209.
25. Nabholtz, J, Pienkouski, T, Mackey, J, et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxourbicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: Interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol. 2002;21:A141.
26. O'Shaughnessy, J. Developments in the systemic therapy of early-stage breast cancer. Eur J Cancer Suppl. 2007;5:3–10.
27. O'Shaughnessy, J, Nag, S, Calderillo-Ruiz, G, et al. Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): Interim results of a global phase III study [abstract 25]. ASCO. 2003;22:7.
28. Overmoyer, B, Silverman, P, Leeming, R, et al. Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer. J Clin Oncol. 2004;22 (Suppl):727.
29. Overmoyer, B, Silverman, P, Leeming, R, et al. Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer. Breast Cancer Res Treat. 2004;88:S106.
30. Piccart-Gebhart, MJ, Procter, M, Leyland-Jones, B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1672.
31. Sartor, CI, Fitzgerald, F, Laurie, B, et al. Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control for node positive breast cancer in CALGB 9344. Proc Am Soc Clin Oncol. 2003;22:30–40.
32. Sartor, CI, Peterson, BL, Woolf, S, et al. Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: Cancer and leukemia group B 9344. J Clin Oncol. 2005;23:5–7.
33. Scherer, R, Langenberg, P. von Elm E. Full publication of results initially presented in abstracts. Cochrane Database Syst Rev. 2007;2.
34. Schrag, D. The price tag on progress – chemotherapy for colorectal cancer. N Engl J Med. 2004;351:317–319.
35. Sherrill, B, Allshouse, A, Amonkar, M, et al. A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis comparing lapatinib plus capecitabine compared to capecitabine for metastatic breast cancer (MBC). J Clin Oncol. 2007;25:A18.
36. Shields, PG. Publication bias is a scientific problem with adverse ethical outcomes: The case for a section for null results. Cancer Epidemiol Biomarkers Prev. 2000;9:771–772.
37. Slamon, D, Eiermann, W, Robert, N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC (R) T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC (R) TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat. 2005;94:S5.
38. Slamon, DJ. Second interim efficacy analysis of the BCIRG 006 trial: Adjuvant chemotherapy with or without trastuzumab in HER2-overexpressing breast cancer. Clin Breast Cancer. 2007;7:449–450.
39. Smith, I, Procter, M, Gelber, RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet. 2007;369:29–36.
40. Smith, IE; on behalf of the HERA study team. Trastuzumab following adjuvant chemotherapy in HER2-positive early breast cancer (HERA trial): Disease-free and overall survival after 2 year median follow-up. ASCO. 2006; Scientific Special Session.
41. Spielmann, M, Roche, H, Delozier, T, et al. Safety analysis from PACS 04: A phase III trial comparing 6 cycles of FEC100 with 6 cycles of ET75 for node-positive early breast cancer patients, followed by sequential trastuzumab in HER2+ patients: Preliminary results. J Clin Oncol. 2006;24:632.
42. Takeda, A, Loveman, E, Harris, P, et al. Time to full publication of studies of novel chemotherapy drugs for breast cancer, and the potential for publication bias. HTA. 2008;12:1–68.
43. The HERA study team. Trastuzumab (H: Herceptin (R)) following adjuvant chemotherapy (CT) significantly improves disease-free survival (DFS) in early breast cancer (BC) with HER2 overexpression: The HERA Trial. Breast Cancer Res Treat. 2005;94:S9.
44. Trotta, F, Apolone, G, Garattini, S, et al. Stopping a trial early in oncology: For patients or for industry? Ann Oncol. 2008;19:1347–1353.
45. Von Minckwitz, G, Raab, G, Schuette, M, et al. Dose-dense versus sequential adriamcycin / docetaxel combination as preoperative chemotherapy (pCHT) in operable breast cancer (T2-3, N0-2,M0)—primary endpoint analysis of the GEPARDUO-Study. Proc Am Soc Clin Oncol. 2002;21:A168.
46. Wagner, LI, Wang, M, Miller, K, et al. Health-related quality of life among patients with metastatic breast cancer receiving paclitaxel versus paclitaxel plus bevacizumab: Results from the eastern cooperative oncology group (ECOG) study E2100. Breast Cancer Res Treat. 2006;100:S239.
47. Wakelee, H. In focus: Non-small cell lung cancer: E1505. Clin Adv Hematol Oncol. 2007;5:206–207.